Boehringer Ingelheim highlights growth targets for expanded animal health business

Boehringer Ingelheim has detailed its growth projections for its animal health business, which has become a central part of the company's overall strategy in recent months.

A recent asset swap with Sanofi saw Boehringer Ingelheim take control of the formerly Sanofi-owned animal health business Merial, the acquisition of which was finalised on January 1st 2017.

In 2016, the division's net sales rose by 8.5 percent year over year in currency adjusted terms to 1.46 billion euros (1.24 billion pounds), with this total now expected to more than double in 2017 due to the Merial integration.

The new-look business is now the second largest company in the global animal health market, and is the top provider worldwide of parasiticides and vaccines for both production animals and pets, as well as being the global leader in the pet, swine, equine and veterinary public health categories.

In future, it will represent over 25 percent of Boehringer Ingelheim's total revenue and employ more than 10,000 people.

Joachim Hasenmaier, head of Boehringer Ingelheim's animal health business unit, said: "By combining two dynamic companies that share the same long-term strategic vision, we are delivering a larger and more innovative portfolio of products and services to prevent disease and improve the health and productivity of animals around the world."

With over 20 years of experience within the animal health market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current animal health roles we have available, you can search for the latest job roles, register your details, or contact the team today.